Rapid development of a DNA vaccine for Zika virus.
Rapid development of a DNA vaccine for Zika virus.
复制标题
DOI：
10.1126/science.aai9137
复制
发表时间：
2016-10-14
期刊：
影响因子：
--
通讯作者：
Graham BS
中科院分区：
文献类型：
--
作者：
Dowd KA;Ko SY;Morabito KM;Yang ES;Pelc RS;DeMaso CR;Castilho LR;Abbink P;Boyd M;Nityanandam R;Gordon DN;Gallagher JR;Chen X;Todd JP;Tsybovsky Y;Harris A;Huang YS;Higgs S;Vanlandingham DL;Andersen H;Lewis MG;De La Barrera R;Eckels KH;Jarman RG;Nason MC;Barouch DH;Roederer M;Kong WP;Mascola JR;Pierson TC;Graham BS
寨卡病毒(ZIKV)在2015年美洲和加勒比海爆发期间被确定为先天性疾病的原因之一。由于地方病和与旅行有关的暴露持续存在胎儿风险，因此必须研制一种疫苗来预防育龄妇女及其伴侣的病毒血症。表达ZIKV PRM和E蛋白的DNA疫苗对小鼠和非人灵长类动物具有免疫原性，对ZIKV攻击后病毒血症的保护作用与血清中和活性有关。这些数据不仅表明DNA疫苗可能是预防ZIKV感染的一种成功方法，而且还表明疫苗诱导的中和活性的保护性阈值将防止急性感染后的病毒血症。
Zika virus (ZIKV) was identified as a cause of congenital disease during an explosive outbreak in the Americas and Caribbean in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of child-bearing age and their partners is imperative. Vaccination with DNA expressing the prM and E proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine-induced neutralizing activity that will prevent viremia following acute infection.